Springer Health+ IME
@SpringerIME
Springer Health+ IME, providing independent medical education in Neurology, Diabetes, Oncology, Rare Diseases, Endocrinology, and Paediatrics.
New phase 2 trial findings published in The Lancet Diabetes & Endocrinology suggest burosumab treatment for X-linked hypophosphataemia (XLH) may begin in the first year of life. Unpick the findings in our latest article.
Key talking points from the latest Alzheimer's conferences. Dorota Religa and Robert Perneczky expand on the breaking data from AD/PDTM and CONy and discuss what it may mean for future clinical practice.
